Glen Eagle Advisors, LLC Tg Therapeutics, Inc. Transaction History

Glen Eagle Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $1,332 - $1,919	-100 Closed	0 $0
Q4 2018 Aug 13, 2024	SELL	$3.44 - $5.76 $344 - $576	-100 Closed	0 $0
Q1 2018 Aug 14, 2024	BUY	$8.7 - $16.8 $869 - $1,680	100 New	100 $1.42 Million
Q3 2017 Aug 13, 2024	BUY	$10.0 - $12.7 $1,000 - $1,270	100 New	100 $1.19 Million
Q2 2017 Aug 12, 2024	BUY	N/A	100	100 $1.01 Million

312

93M

1.9M

1.45M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.95B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.